Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma.

ABSTRACT: Epithelial-myoepithelial carcinoma (EMC) is a rare subtype of salivary gland neoplasms. Since the initial description of the cancer, just over 300 cases have been reported. EMCs occupy a biphasic cellular differentiation-state defined by the constitution of two cell types representing epithelial and myoepithelial lineages, yet the functional consequence of the differentiation-state heterogeneity with respect to therapy resistance of the tumors remains unclear. The reported local recurrence rate of the cases is approximately 30%, and while distant metastases are rare, a significant fraction of these cases are reported to receive no survival benefit from radio- or chemotherapy given in addition to surgery. Moreover, no targeted therapies have been reported for these neoplasms. We report here

SUBMITTER: Makela R 

PROVIDER: S-EPMC7341452 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature